Cargando…

Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Valganciclovir (VGC), an oral prodrug of ganciclovir (GCV), has been shown to clear cytomegalovirus (CMV) viremia in preemptive treatment of patients after allogeneic hematopoietic stem cell transplantation (alloHSCT), apparently without significant toxicity. Since VGC obviates hospitalization, it i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barkam, Corinna, Kamal, Haytham, Dammann, Elke, Diedrich, Helmut, Buchholz, Stefanie, Eder, Matthias, Krauter, Jürgen, Ganser, Arnold, Stadler, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518946/ https://www.ncbi.nlm.nih.gov/pubmed/23243512 http://dx.doi.org/10.1155/2012/874601

Ejemplares similares

The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease
por: Stadler, Michael, et al.
Publicado: (2023)

Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation
por: Weissinger, E M, et al.
Publicado: (2013)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation
por: Borchers, Sylvia, et al.
Publicado: (2012)

Correction: Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation
por: Borchers, Sylvia, et al.
Publicado: (2013)

Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation
por: Varanasi, Pavankumar Reddy, et al.
Publicado: (2019)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis
por: Stadler, Michael, et al.
Publicado: (2022)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Adaptive NK cells undergo a dynamic modulation in response to human cytomegalovirus and recruit T cells in in vitro migration assays
por: Basílio-Queirós, Débora, et al.
Publicado: (2022)

VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation
por: Sethi, Maya K., et al.
Publicado: (2017)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
por: Torii, Yuka, et al.
Publicado: (2023)

Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy
por: Kim, Tark, et al.
Publicado: (2016)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy
por: Kalil, Andre C., et al.
Publicado: (2009)

Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection
por: Wong, Victoria WY, et al.
Publicado: (2012)

Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection
por: Ohyama, Shohei, et al.
Publicado: (2019)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation
por: Papazian, Laurent, et al.
Publicado: (2021)

Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation
por: Hümmert, Martin W., et al.
Publicado: (2021)

1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants
por: Catho, Gaud, et al.
Publicado: (2018)

Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant
por: Chiereghin, Angela, et al.
Publicado: (2021)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

Another tool against cytomegalovirus after allogeneic hematopoietic cell transplantation
por: Chen, George L., et al.
Publicado: (2023)

Case report: severe cytomegalovirus primary infection in an immunocompetent adult with disseminated intravascular coagulation treated with valganciclovir
por: Müller, Niklas F., et al.
Publicado: (2016)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
por: Tripathy, Koushik, et al.
Publicado: (2017)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT Compliant)
por: Morioka, Ichiro, et al.
Publicado: (2020)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Stern, Lauren, et al.
Publicado: (2019)

Incidence of UL97 Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving 6 Months of Oral Valganciclovir Therapy
por: James, Scott H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_am2l0cm0r2ls48ckenp28a5h1p